FONTANA, DILETTA
FONTANA, DILETTA
DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)
Large-Scale Analysis of SARS-CoV-2 Synonymous Mutations Reveals the Adaptation to the Human Codon Usage During the Virus Evolution
2022 Ramazzotti, D; Angaroni, F; Maspero, D; Mauri, M; D’Aliberti, D; Fontana, D; Antoniotti, M; Elli, E; Graudenzi, A; Piazza, R
Impact of ETNK1 somatic mutations on phosphoethanolamine synthesis, ROS production and DNA damage
2021 Fontana, D; Gambacorti Passerini, C; Piazza, R
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma
2021 Arosio, G; Sharma, G; Villa, M; Mauri, M; Crespiatico, I; Fontana, D; Manfroni, C; Mastini, C; Zappa, M; Magistroni, V; Ceccon, M; Redaelli, S; Massimino, L; Garbin, A; Lovisa, F; Mussolin, L; Piazza, R; Gambacorti Passerini, C; Mologni, L
Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia
2021 Fontana, D; Gambacorti Passerini, C; Piazza, R
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia
2020 Fontana, D; Ramazzotti, D; Aroldi, A; Redaelli, S; Magistroni, V; Pirola, A; Niro, A; Massimino, L; Mastini, C; Brambilla, V; Bombelli, S; Bungaro, S; Morotti, A; Rea, D; Stagno, F; Martino, B; Campiotti, L; Caocci, G; Usala, E; Merli, M; Onida, F; Bregni, M; Elli, E; Fumagalli, M; Ciceri, F; Perego, R; Pagni, F; Mologni, L; Piazza, R; Gambacorti-Passerini, C
Germ-Line TP53 Mutation in an Adolescent With CMML/Atypical CML and Familiar Cancer Predisposition
2020 Nucera, S; Fazio, G; Piazza, R; Rigamonti, S; Fontana, D; Gambacorti Passerini, C; Maitz, S; Rovelli, A; Biondi, A; Cazzaniga, G; Balduzzi, A
Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation
2020 Diral, E; Mori, S; Antolini, L; Abruzzese, E; Le Coutre, P; Martino, B; Pungolino, E; Elena, C; Bergamaschi, M; Assouline, S; Di Bona, E; Gozzini, A; Andrade-Campos, M; Stagno, F; Iurlo, A; Pirola, A; Fontana, D; Petiti, J; Bonanomi, M; Crivori, P; Piazza, R; Fava, C; Gambacorti Passerini, C
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy
2020 Bossi, E; Aroldi, A; Brioschi, F; Steidl, C; Baretta, S; Renso, R; Verga, L; Fontana, D; Sharma, G; Mologni, L; Mussolin, L; Piazza, R; Gambacorti Passerini, C
ETNK1 mutations in atypical chronic myeloid leukemia induce a mutator phenotype that can be reverted with phosphoethanolamine
2020 Fontana, D; Mauri, M; Renso, R; Docci, M; Crespiatico, I; Rost, L; Jang, M; Niro, A; D'Aliberti, D; Massimino, L; Bertagna, M; Zambrotta, G; Bossi, M; Citterio, S; Crescenzi, B; Fanelli, F; Cassina, V; Corti, R; Salerno, D; Nardo, L; Chinello, C; Mantegazza, F; Mecucci, C; Magni, F; Cavaletti, G; Bruheim, P; Rea, D; Larsen, S; Piazza, R; Gambacorti-Passerini, C
Characterization of the role of mutated ETNK1 in the onset of atypical Chronic Myeloid Leukemia
2019 Fontana, D
Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients
2019 Fontana, D; Ramazzotti, D; Aroldi, A; Niro, A; Massimino, L; Rea, D; Stagno, F; Martino, B; Campiotti, L; Caocci, G; Elli, E; Fumagalli, M; Ciceri, F; Piazza, R; GAMBACORTI PASSERINI, C
Phase ii study with crizotinib in patients with anaplastic lymphoma kinase (alk)-positive lymphoma relapsed/refractory to chemotherapy
2019 Bossi, E; Brioschi, F; Steidl, C; Baretta, S; Cantu, S; Verga, L; Fontana, D; Sharma, G; Mologni, L; Mussolin, L; Piazza, R; Gambacorti Passerini, C
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways
2019 Magistroni, V; Mauri, M; D'Aliberti, D; Mezzatesta, C; Crespiatico, I; Nava, M; Fontana, D; Sharma, N; Parker, W; Schreiber, A; Yeung, D; Pirola, A; Redaelli, S; Massimino, L; Wang, P; Khandelwal, P; Citterio, S; Viltadi, M; Bombelli, S; Rigolio, R; Perego, R; Boultwood, J; Morotti, A; Saglio, G; Dong-Wook, K; Branford, S; Gambacorti Passerini, C; Piazza, R
ETNK1 mutations promote ROS production and DNA damage through increased mitochondrial activity
2018 Fontana, D; Mauri, M; Niro, A; Massimino, L; Bertagna, M; Zambrotta, G; Bossi, M; Citterio, S; Crescenzi, B; Signore, G; Piazza, V; Mecucci, C; Cavaletti, G; Rea, D; Gambacorti-Passerini, C; Piazza, R
Erratum: Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design (Journal of Medicinal Chemistry (2017) 60:22 (9205-9221) DOI: 10.1021/acs.jmedchem.7b01039)
2018 Mah, S; Park, J; Jung, H; Ahn, K; Choi, S; Tae, H; Jung, K; Rho, J; Lee, J; Passerini, C; Fontana, D; Hong, S; Hong, S
ETNK1 MUTATIONS INCREASE MITOCHONDRIAL ACTIVITY AND PROMOTE DNA DAMAGE THROUGH ROS PRODUCTION
2018 Fontana, D; Mauri, M; Niro, A; Massimino, L; Bertagna, M; Zambrotta, G; Bossi, M; Citterio, S; Crescenzi, B; Signore, G; Piazza, V; Mecucci, C; Cavaletti, G; Rea, D; Gambacorti-Passerini, C; Piazza, R
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates
2017 Farina, F; Ceccon, M; Mori, S; Verga, L; Borin, L; Mologni, L; Fontana, D; Geeta, G; Piazza, R; Gambacorti-Passerini, C
Abstract 3583: Drug-resistant NPM/ALK mutants show different sensitivity to second generation tyrosine kinase inhibitors
2015 Mologni, L; Ceccon, M; Fontana, D; Pirola, A; Piazza, R; Gambacorti-Passerini, C
Erratum: Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma (Molecular Cancer Research (2015) 13 (775-783))
2015 Ceccon, M; Mologni, L; Giudici, G; Piazza, R; Pirola, A; Fontana, D
ETNK1 is an early event and SETBP1 a late event in atypical Chronic Myeloid Leukemia
2015 Niro, A; Piazza, R; Merati, G; Pirola, A; Donadoni, C; Fontana, D; Redaelli, S; Mezzatesta, C; Renso, R; Farina, F; Rea, D; Gambacorti-Passerini, C